Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 551 to 560 of 1514 total matches.
Octreotide - A Synthetic Somatostatin
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989 (Issue 796)
Med, 107:162, 1987). For patients with
The Medical Letter, Vol. 31 (Issue 796) July 14, 1989, pp. 66 ...
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Carteolol and Penbutolol For Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989 (Issue 797)
; neither should be taken by nursing mothers.
The Medical Letter, Vol. 31 (Issue 797) July 28, 1989, pp. 70 ...
Carteolol (Cartrol - Abbott) and penbutolol (Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of systemic hypertension. Both drugs are non-selective beta-blockers with mild partial agonist activity. Beta-blockers currently available in the USA for treatment of hypertension are listed in the table on the next page.
Adjuvant Chemotherapy of Early Breast Cancer
The Medical Letter on Drugs and Therapeutics • May 18, 1990 (Issue 818)
increased survival in premeno- pausal node-positive patients
The Medical Letter, Vol. 32 (Issue 818) May 18 ...
The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free of disease; about 30% will have relapsed or died. Patients with positive nodes may have a 30% to 60% relapse rate, depending on the number of positive nodes and other prognostic factors, such as the presence of estrogen receptors (IC Henderson et al, in VT DeVita, Jr et al, eds, Cancer: Principles and Practice of Oncology, 3rd ed, Philadelphia:Lippincott, 1989, p 1197). Which of...
Olsalazine
The Medical Letter on Drugs and Therapeutics • Nov 16, 1990 (Issue 831)
ulcerative colitis compared
The Medical Letter, Vol. 32 (Issue 831) November 16, 1990, pp. 105-106 ...
Olsalazine sodium (Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine (Azulfidine; and others).
Mifepristone (RU 486)
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990 (Issue 833)
, Vol. 32 (Issue 833) December 14, 1990, pp. 112-113
Copyright The Medical Letter
UNAUTHORIZED ...
Recent articles in the press have suggested that mifepristone (RU 486 - Roussel Uclaf) can effectively and safely induce an abortion. The drug is currently available only in France and China, but the manufacturer has also applied for a license in the United Kingdom. Mifepristone has been used on an investigational basis in the USA as an abortifacient and for treatment of Cushing's disease and breast cancer, but no manufacturer has applied to the US Food and Drug Administration for approval to market the drug in this country.
Doxazosin For Treatment of Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 22, 1991 (Issue 838)
).
The Medical Letter, Vol. 33 (Issue 838) February 22, 1991, pp. 15-16
Copyright The Medical Letter ...
Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin (Minipress, and others) and terazosin (Hytrin), was recently approved by the US Food and Drug Administration for treatment of hypertension.
Alprazolam For Panic Disorder
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991 (Issue 841)
to six weeks with imipramine. About
The Medical Letter, Vol. 33 (Issue 841) April 5, 1991, pp. 30-31 ...
Alprazolam (Xanax - Upjohn), a triazolobenzodiazepine previously available in the USA for treatment of anxiety (Medical Letter 24:41, 1982), was recently approved by the US Food and Drug Administration (FDA) for treatment of panic disorder, with or without agoraphobia. According to one report, alprazolam was the fifth most widely prescribed drug in the USA last year (American Medical News, March 4, 1991, page 4).
Ophthalmic Ciprofloxacin
The Medical Letter on Drugs and Therapeutics • May 31, 1991 (Issue 845)
.
The Medical Letter, Vol. 33 (Issue 845) May 31, 1991, pp. 52-53
Copyright The Medical Letter
UNAUTHORIZED ...
An ophthalmic formulation of ciprofloxacin hydrochloride (Ciloxan - Alcon), a fluoroquinolone antibiotic, was recently marketed in the USA for treatment of bacterial keratitis and conjunctivitis. Ciprofloxacin has been used orally (Cipro) to treat a variety of serious infections (Medical Letter, 30:11, 1988) and recently was approved for intravenous administration.
Safety of Terfenadine and Astemizole
The Medical Letter on Drugs and Therapeutics • Feb 07, 1992 (Issue 863)
). These patients both denied overdosage, but
had high serum concentrations of the drug.
The Medical Letter, Vol ...
Terfenadine (Seldane - Marion Merrell Dow) and astemizole (Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989). Both are available without a prescription in Canada, and the US Food and Drug Administration is apparently considering terfenadine for over-the-counter availability in the USA.
Nicotine Patches
The Medical Letter on Drugs and Therapeutics • Apr 17, 1992 (Issue 868)
(compared to 39% with placebo);
The Medical Letter, Vol. 34 (Issue 868) April 17, 1992, pp. 37-38 ...
Three nicotine-releasing adhesive patches for the skin (Habitrol - Ciba-Geigy; Nicoderm - Marion Merrell Dow; and PROSTEP - Lederle) have been approved by the US Food and Drug Administration to aid withdrawal from smoking. Nicotrol (Parke-Davis) may also be approved soon. All the manufacturers recommend using the patches in conjunction with a behavioral modification program.